Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients (GLOW4)

A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Tolerability of NVA237 (50µg o.d.) Using Tiotropium (18µg o.d.) as an Active Control in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD) .

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease
• Intervention / Treatment: Drug: NVA237; Drug: Tiotropium

• Study Type: Interventional
• Enrollment (Actual): 211
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Fukuoka, Japan, 812-0033
    • Novartis Investigative Site
  • Kochi, Japan, 780-8077
    • Novartis Investigative Site
  • Osaka, Japan, 545-8586
    • Novartis Investigative Site
  • Osaka, Japan, 530-0012
    • Novartis Investigative Site
  • Saitama, Japan, 337-0012
    • Novartis Investigative Site
  • Fukuoka
    • Iizuka, Fukuoka, Japan, 820-8505
      • Novartis Investigative Site
    • Kitakyushu, Fukuoka, Japan, 802-0083
      • Novartis Investigative Site
    • Kitakyushu, Fukuoka, Japan, 820-0052
      • Novartis Investigative Site
    • Kurume, Fukuoka, Japan, 830-0011
      • Novartis Investigative Site
    • Onojo, Fukuoka, Japan, 816-0931
      • Novartis Investigative Site
    • Yanagawa, Fukuoka, Japan, 832-0059
      • Novartis Investigative Site
  • Hokkaido
    • Asahikawa, Hokkaido, Japan, 070-8644
      • Novartis Investigative Site
    • Obihiro, Hokkaido, Japan, 080-0805
      • Novartis Investigative Site
    • Sapporo, Hokkaido, Japan, 060-8648
      • Novartis Investigative Site
  • Hyogo
    • Himeji-city, Hyogo, Japan, 672-8064
      • Novartis Investigative Site
    • Takarazuka, Hyogo, Japan, 665-0827
      • Novartis Investigative Site
    • Yabu, Hyogo, Japan, 667-8555
      • Novartis Investigative Site
  • Ibaraki
    • Inashiki-gun, Ibaraki, Japan, 300-0395
      • Novartis Investigative Site
    • Naka-gun, Ibaraki, Japan, 319-1113
      • Novartis Investigative Site
    • Sashima-gun, Ibaraki, Japan, 306-0433
      • Novartis Investigative Site
  • Iwate
    • Morioka, Iwate, Japan, 020-0055
      • Novartis Investigative Site
  • Kanagawa
    • Kawasaki, Kanagawa, Japan, 210-0852
      • Novartis Investigative Site
    • Yokohama, Kanagawa, Japan, 232-0021
      • Novartis Investigative Site
    • Yokohama, Kanagawa, Japan, 236-0051
      • Novartis Investigative Site
  • Kyoto
    • Uji, Kyoto, Japan, 611-0042
      • Novartis Investigative Site
  • Mie
    • Matsusaka-city, Mie, Japan, 515-8544
      • Novartis Investigative Site
  • Miyagi
    • Sendai, Miyagi, Japan, 981-8563
      • Novartis Investigative Site
  • Niigata
    • Nagaoka, Niigata, Japan, 940-8653
      • Novartis Investigative Site
    • Nagaoka-City, Niigata, Japan, 940-2085
      • Novartis Investigative Site
  • Okayama
    • Kasaoka, Okayama, Japan, 714-0081
      • Novartis Investigative Site
    • Tsuyama, Okayama, Japan, 708-0841
      • Novartis Investigative Site
  • Osaka
    • Osakasayama, Osaka, Japan, 589-0022
      • Novartis Investigative Site
    • Sakai, Osaka, Japan, 591-8555
      • Novartis Investigative Site
    • Takatsuki, Osaka, Japan, 569-1096
      • Novartis Investigative Site
  • Tochigi
    • Shimotsuka-gun, Tochigi, Japan, 321-0293
      • Novartis Investigative Site
  • Tokyo
    • Bunkyo-ku, Tokyo, Japan, 113-8431
      • Novartis Investigative Site
    • Nakano-ku, Tokyo, Japan, 164-0012
      • Novartis Investigative Site
    • Ohta-ku, Tokyo, Japan, 140-0063
      • Novartis Investigative Site
  • Yamagata
    • Yamagata city, Yamagata, Japan, 990-8533
      • Novartis Investigative Site
  • Yamaguchi
    • Ube, Yamaguchi, Japan, 755-0241
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with moderate to severe stable COPD (Stage II or Stage III) according to the Gold Guideline 2008.
• Current or ex-smokers who have a smoking history of at least 10 pack years.
• Patients with a post-bronchodilator FEV1 ≥30% and < 80% of the predicted normal, and postbronchodilator FEV1/FVC < 0.7 at Visit 2 (day -7)

Exclusion Criteria:

• Pregnant women or nursing mothers or women of child-bearing potential not using an acceptable method of contraception
• Patients requiring long term oxygen therapy
• Patients who have had a lower respiratory tract infection within 6 weeks prior to Visit 1
• Patients with concomitant pulmonary disease
• Patients with a history of asthma
• Any patient with lung cancer or a history of lung cancer
• Patients with a history of certain cardiovascular comorbid conditions
• Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
• Patients in the active phase of a supervised pulmonary rehabilitation program
• Patients contraindicated for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents
• Other protocol-defined inclusion/exclusion criteria may apply

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NVA237; 50µg once daily	Drug: NVA237; 50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
Experimental: Tiotropium; 18µg once daily	Drug: Tiotropium; 18µg capsules for inhalation, delivered via HandiHaler®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Adverse Events, Serious Adverse Events or Death	Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.	52 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients With Newly Occurring or Worsening Clinically Notable Vital Signs Values at Any Timepoint Over the Whole Treatment Period	Clinically notable vital sign values were: pulse rate - low, <40 bpm or <=50 bpm and decrease from baseline >=15bpm; pulse rate high, >130 bpm or >=120bpm and increase from baseline >=15 bpm. Systolic blood pressure - low, <75 mmHg or <=90 mmHg and decrease from baseline >=20 mmHg; high, >200 mmHg or >=180 mmHg and increase from baseline >=20 mmHg. Diastolic blood pressure - low, <40 mmHg or <=50 mmHg and decrease from baseline >=15 mmHg; high, >115 mmHg or >=105 mmHg and increase from baseline >=15 mmHg.	52 weeks
Number of Patients With Notable Change From Baseline in Fridericia's QTc Values at Any Timepoint Over the Whole Treatment Period	Clinically notable change from baseline was and increase from baseline of 30 or greater milliseconds (ms).	52 weeks
Change in Pre-dose FEV1 From Baseline	Pre-dose FEV1 is defined as the average of the measurements at 45 and 15 minutes pre-dose.	Weeks 12, 24, 36 and 52
Change in Pre-dose FVC From Baseline	Pre-dose FVC is defined as the average of the measurements at 45 and 15 minutes pre-dose.	Weeks 12, 24, 36 and 52
Time From Randomization Until the Start of the First Moderate or Severe COPD Exacerbation	Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required. Participants who withdraw from the study and do not experience a moderate or severe exacerbation are censored at the date of withdrawal. Participants who complete the study and do not experience a moderate or severe exacerbation are censored at the completion visit date.	52 weeks
Number of Patients With Moderate or Severe COPD Exacerbations	Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required.	52 weeks
Change in St. George Respiratory Questionnaire From Baseline	SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life.	Weeks 12, 24, 36, 52
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over the Whole Treatment Period	Patients recorded rescue medication use in a paper patient diary. If a patient required the use of salbutamol as rescue medication due to an increase in COPD symptoms, the number of inhalations (puffs) taken was recorded in the patient diary.	52 weeks
Number of Patients With Newly Occurring or Worsening Clinically Notable Hematology Values at Any Timepoint Over the Whole Treatment Period	Clinically notable hematology values were: hemoglobin - male <11.5g/dL, female <9.5 g/dL; hematocrit - male <37%, female <32%; white cell count - <2800µL or >16000µL; platelets - <7.5 10*4/µL or >70.0 10*4/µL	52 weeks
Number of Patients With Newly Occurring or Worsening Clinically Notable Biochemistry Values at Any Timepoint Over the Whole Treatment Period	Clinically notable biochemistry values were: total protein - <4.0 g/dL or >9.5 g/dL; albumin <2.5 g/dL; bilirubin (total) >1.9 mg/dL; BUN >27 mg/dL; creatinine >1.99 mg/dL; AST >3 x ULN U/L; ALT >3 x ULN U/L; ALP >3 x ULN U/L; y-GTP >3 x ULN U/L; sodium <125 mEq/L or >160 mEq/L; potassium <3.0 mEq/L or >6.0 mEq/L; glucose <51.0 mg/dL or >180.0 mg/dL	52 weeks

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start: May 1, 2010
• Primary Completion (Actual): November 1, 2011

Study Registration Dates

• First Submitted: May 5, 2010
• First Submitted That Met QC Criteria: May 7, 2010
• First Posted (Estimate): May 10, 2010

Study Record Updates

• Last Update Posted (Estimate): January 18, 2013
• Last Update Submitted That Met QC Criteria: December 12, 2012
• Last Verified: November 1, 2012

More Information

Terms related to this study

• Keywords: COPD; NVA237
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Parasympatholytics; Autonomic Agents; Peripheral Nervous System Agents; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Adjuvants, Anesthesia; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Glycopyrrolate; Tiotropium Bromide
• Other Study ID Numbers: CNVA237A1302